An immune-active tumor microenvironment favors clinical response to ipilimumab
about
Checkpoint Inhibitors and Their Application in Breast CancerClinical utility of nivolumab in the treatment of advanced melanomaImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumNovel technologies and emerging biomarkers for personalized cancer immunotherapyExploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesViro-immune therapy: A new strategy for treatment of pancreatic cancerExercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and ProgressionImmune checkpoint inhibitors: therapeutic advances in melanomaPredictive factors for immunotherapy in melanomaCo-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentControl of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentIpilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaAcquired and intrinsic resistance in cancer immunotherapyImmune Checkpoint Blockade in Cancer TherapyCTLA-4 blockade in tumor models: an overview of preclinical and translational researchPrimer on tumor immunology and cancer immunotherapyInnate and adaptive immune cells in the tumor microenvironmentThe STING pathway and the T cell-inflamed tumor microenvironmentPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.The blockade of immune checkpoints in cancer immunotherapyHigh-content molecular profiling of T-cell therapy in oncologyThe role of immune checkpoint inhibition in the treatment of ovarian cancerHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsNew perspectives on type I IFNs in cancerAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyGenetic basis for clinical response to CTLA-4 blockade in melanomaColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeControl of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Rational combinations of immunotherapeutics that target discrete pathways.Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulationAt the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis
P2860
Q26745442-6140AB59-16D9-4F43-8BBF-B001F5B9DF23Q26751268-3319EC1F-EC1B-4680-AC67-12DE4B7E628EQ26765459-FF384087-510E-47B5-8EC4-7A604523FBABQ26770780-78631931-8B4C-4D5E-971E-5CD5D52D5F6DQ26772715-3BB4A643-870D-4F7F-BF37-2767011A7858Q26774641-6E5855DE-6FFB-4626-A5C5-CCFB33A6E3F1Q26775189-2BB3E35F-872A-421E-A9EA-B40B5170DAF3Q26775591-BB194EC1-51B2-4040-8D1D-157E58259F72Q26778765-660A2EBC-1FF8-4795-9C7D-F37BDFE0F6A6Q26796099-598FCCD7-3760-4FBC-B9E0-6008FECACF34Q26796305-8B65EE2A-3DC1-42F2-B944-3065173E649CQ26799117-57227FEA-2EA0-4DAC-A27E-7BCF4C9AB3F1Q26824310-FF9D7023-E393-4CF3-AFF5-8EA9541DE7A3Q26827701-73D04F9A-08EA-4016-90CF-3E05CEF12D8AQ26830509-2CF60C01-7BAF-46F4-8B82-D40F15533920Q26992295-74B2E3DF-60F0-498D-B439-408308B6FC69Q27001126-D6E63473-0E33-4779-A0F7-0FDB723DA374Q27008342-6C413D4A-88E1-44DA-8E92-C8321CFBE4CBQ27008371-3880B146-9DB5-4461-A760-7AF9D8FB77B0Q27853353-8E657F98-629A-4B14-806D-5F01C61FDD25Q27860852-4E02D69F-9D60-4F6F-8779-5CD5E213A42EQ28066792-B0E21B00-D8CB-4943-B9F8-D24896E0872EQ28077924-72013FA1-700B-4AC1-8B10-42DBA8267B54Q28086999-6578E350-6C7D-4602-A101-98466DE957ABQ28256099-A4E55852-D49E-4A3B-82C8-B74E809D94B4Q29617774-8A2F53C9-BA75-4974-BE8A-DF8FD72B5D03Q29620594-EA7B0450-D6E5-40E3-9759-D9E5A8C8EC31Q29620881-711A2F66-E9F2-43A4-98BE-BACEAC589E43Q29994573-F4638EAE-D98A-48B9-9553-1516F6D548F2Q30276649-2FF99BEC-2F1B-4AAC-AC23-FE1018F6C2CDQ30846001-78255B76-2935-4E9E-8EE1-C0B8F3753560Q33606144-5EF95D9B-8192-4963-BEB5-D86A9EF349C9Q33631126-8E5CB891-54BA-4C54-A967-B71FD097CAE6Q33732329-17579D07-A367-44CB-85B7-B23F4CAC4C0DQ33750137-9AFC33C5-D646-41FB-8176-EBE74ACDDF33Q33788685-3736C692-68EB-411F-BEE0-1071970D9D40Q33813057-A04A8F4A-E8C8-4D4D-AE43-2A03A5B308C8Q33933665-CB6D644D-7A51-45AC-AF4B-F7D94EC1E7B3Q34016867-0DAB87BA-09BF-4198-B2BD-24D8310BF975Q34338284-2AFAB711-DDEE-4B2B-8BB4-1D97B13A59CF
P2860
An immune-active tumor microenvironment favors clinical response to ipilimumab
description
article
@en
im Juli 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2012
@uk
name
An immune-active tumor microenvironment favors clinical response to ipilimumab
@en
An immune-active tumor microenvironment favors clinical response to ipilimumab
@nl
type
label
An immune-active tumor microenvironment favors clinical response to ipilimumab
@en
An immune-active tumor microenvironment favors clinical response to ipilimumab
@nl
prefLabel
An immune-active tumor microenvironment favors clinical response to ipilimumab
@en
An immune-active tumor microenvironment favors clinical response to ipilimumab
@nl
P2093
P1476
An immune-active tumor microenvironment favors clinical response to ipilimumab
@en
P2093
David Berman
Henrik Schmidt
Jeffrey R Jackson
John Cogswell
Maria Jure-Kunkel
Nathan O Siemers
Omid Hamid
Scott D Chasalow
P2888
P304
P356
10.1007/S00262-011-1172-6
P407
P577
2012-07-01T00:00:00Z